[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100289786":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":31,"locations":40,"responsibleParty":69,"collaborators":72,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":84,"minAge":10,"maxAge":10,"enrollmentInfo":85,"targetDuration":10,"studyType":88,"phases":10,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Medizinische Hochschule Brandenburg Theodor Fontane","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with CF",null,"\\>2000 in Germany, France, Italy, Spain, Denmark, Belgium, Portugal, GB, Ireland, USA, Australia, Canada, Brazil, Argentina...",[13],"Diagnostic Test: Questionnaire Patient Reported Outcome Measure (PROM)",{"label":15,"type":10,"description":16,"interventionNames":17},"Age-matched healthy controls","\\>100 in Germany \\>100 in each of the other participating countries",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DIAGNOSTIC_TEST","Questionnaire Patient Reported Outcome Measure (PROM)","non-interventional",[15,9],[25],"routine-care assessments",[27],{"name":28,"affiliation":29,"role":30},"Jochen G Mainz, Prof. MD","Medizinische Hochschule Brandenburg (MHB), University","PRINCIPAL_INVESTIGATOR",[32,36],{"name":28,"role":33,"phone":34,"phoneExt":10,"email":35},"CONTACT","+493381411803","jochen.mainz@mhb-fontane.de",{"name":37,"role":33,"phone":38,"phoneExt":10,"email":39},"Franziska Duckstein, MA","+493381411841","f.duckstein@klinikum-brandenburg.de",[41,62],{"facility":42,"status":43,"city":44,"state":10,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Klinikum Westbrandenburg","RECRUITING","Brandenburg an der Havel","14770","Germany","DE",{"type":49,"coordinates":50},"Point",[51,52],12.55,52.41667,{"lat":52,"lon":51},[55,57,58,61],{"name":56,"role":33,"phone":34,"phoneExt":10,"email":35},"Jochen G Mainz, Prof. Dr.",{"name":37,"role":33,"phone":38,"phoneExt":10,"email":39},{"name":59,"role":60,"phone":10,"phoneExt":10,"email":10},"Carlos Zagoya, PhD","SUB_INVESTIGATOR",{"name":37,"role":60,"phone":10,"phoneExt":10,"email":10},{"facility":29,"status":43,"city":44,"state":10,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":63,"geoPoint":65,"contacts":66},{"type":49,"coordinates":64},[51,52],{"lat":52,"lon":51},[67,68],{"name":56,"role":33,"phone":34,"phoneExt":10,"email":35},{"name":37,"role":33,"phone":10,"phoneExt":10,"email":39},{"type":30,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Prof. Dr. Jochen G. Mainz","Director of the Cystic Fibrosis-Center",[73],{"name":74,"class":6},"University of Jena","100289786","development-and-validation-of-a-disease-specific-prom-to-assess-abdominal-involvement-in-patients-with-cf-cfabd-score-100289786",false,"NCT03052283","Development and Validation of a Disease Specific PROM to Assess Abdominal Involvement in Patients With CF (CFAbd-Score)","Evaluation and Validation of a New Questionnaire to Identify and Quantify Abdominal Symptoms in Patients With Cystic Fibrosis Following FDA Guidelines: the CF Abd-Score (Primarily Named JenAbdomen-CF Score)","CFAbd-Score","Inclusion Criteria:\n\nCF cohort:\n\nDiagnosis of CF determined by\n\n* a sweat chloride of \\>60 mEq\u002FL and\u002For\n* detection of 2 disease causing CFTR mutations with evidence of organ involvement.\n\nHealthy controls:\n\n* Age-matched\n\nExclusion Criteria:\n\nCF cohort:\n\n* Lacking ability to cooperate of patients \u002Ftheir families, respectively\n\nHealthy controls:\n\n* Other diseases causing abdominal symptoms (Inflammatory bowel disease (IBD), alpha 1 antitrypsin deficiency, celiac disease, food allergy, gastroenteritis, etc.)",true,"ALL",{"count":86,"type":87},2000,"ESTIMATED","OBSERVATIONAL","Development, validation and evaluation of a new multimodal questionnaire to assess and quantify the abdominal involvement in patients with the inherited life shortening multi-organ disease Cystic fibrosis.\n\nIn the stepwhise development of the patient reported outcome measures (PROM) repeadedly, CF-patients, their families as well as professionals working in different fields of CF-care will be included.",[91],"Cystic Fibrosis",[93,94,95,96,97,98,99,100,101,102,103],"Cystic fibrosis","Abdomen","Pancreas","Liver","Gut","Symptom Score","Patient reported outcome measure (PROM)","diabetes","CFTR-modulator","Tricafta","Kaftrio","2023-03-31",{"date":106,"type":107},"2023-04-04","ACTUAL",{"date":109,"type":107},"2017-01-26",{"date":111,"type":87},"2027-12-31",{"name":5,"class":6},2]